CG Oncology

CGONNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$6.936 B

$78.25 +4.87%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$161.0M

Loss-making

Shares outstanding

88,640,375

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#18VaxcytePCVX$8.77B
#19ImmunovantIMVT$7.68B
#20CG OncologyCGON$6.94B
#21Scholar RockSRRK$5.87B
#22CRISPR TherapeuticsCRSP$5.64B

What if CG Oncology were worth as much as…

Open the what-if tool →

Gold $30.3T

$341,537.97

Per share 4,365× higher

Bitcoin $1.72T

$19,402.04

Per share 248× higher

Nvidia $5.48T

$61,821.24

Per share 790× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for CG Oncology are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.